OncView™ Podcast: Front-Line Management of Extensive-Stage SCLC
This special edition of the “Oncology Peer Review On-The-Go” podcast hosts Mark Socinski, MD, who discusses important factors in treating and managing extensive-stage small cell lung cancer, and details information from the IMpower133 trial.
As part of the OncView™ video series, CancerNetwork® spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida, about updates in the management of extensive-stage small cell lung cancer (ES-SCLC).
In the video series, Socinski discussed the following:
- Epidemiology and Clinical Course of SCLC
- Evolution of Therapies for SCLC
- Treatment Challenges in Extensive-Stage SCLC
- Immunotherapy as First-Line Treatment for Extensive-Stage SCLC
- The IMpower133 Trial in Extensive-Stage SCLC
- Extensive-Stage SCLC: Implications of IMpower133
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.
Recent Videos
Ongoing Consolidative RT Trial May Support Efficacy Findings in SCLC
PFS Benefit Occurs with Complete vs Incomplete Consolidative RT in ES-SCLC
Assessing Consolidative Radiation in Extensive-Stage Small Cell Lung Cancer
Treating Patients with SCLC with Driver Mutations
Adverse Event Management Practices in SCLC
Treatment Practices for Extended-Stage Small Cell Lung Cancer
Incorporating PCI Following ADRIATIC Study
Treatment Algorithm for Limited-Stage Small Cell Lung Cancer
SCLC is ‘On the Cusp’ of Being Better Understood, Says Expert
Expert Discusses Radiotherapy Recommendations for SCLC Management
